On February 22, 2018 CytomX Therapeutics, Inc. (Nasdaq:CTMX), a clinical-stage biopharmaceutical company developing investigational Probody therapeutics for the treatment of cancer, plans to report full-year 2017 financial results and provide an operational update on March 7, 2018, after the NASDAQ market close (Press release, CytomX Therapeutics, FEB 22, 2018, View Source/phoenix.zhtml?c=254195&" target="_blank" title="View Source/phoenix.zhtml?c=254195&" rel="nofollow">View Source;p=RssLanding&cat=news&id=2334152 [SID1234524125]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Conference Call/Webcast Information
Interested parties may access the live audio webcast of the teleconference at 5:00 p.m. ET through the Investor and News page of CytomX’s website at View Source or by dialing 1-877-809-6037 and using the passcode 5686339.

A replay will be available on the CytomX website or by dialing 1-855-859-2056 and using the passcode 5686339. The replay will be available from March 7, 2018, until March 14, 2018.